LW 1017
Alternative Names: LW-1017Latest Information Update: 23 Jan 2026
At a glance
- Originator Lysoway Therapeutics
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action MCOLN1 protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Frontotemporal dementia; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 06 Jan 2026 Preclinical trials in Alzheimer's disease in USA (PO), prior to January 2026 (Lysoway Therapeutics pipeline, January 2026)
- 06 Jan 2026 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO), prior to January 2026 (Lysoway Therapeutics pipeline, January 2026)
- 06 Jan 2026 Preclinical trials in Frontotemporal dementia in USA (PO), prior to January 2026 (Lysoway Therapeutics pipeline, January 2026)